Myomo Reports Progress with China Joint Venture, Receives Partial Payment of Technology License Fee
BOSTON (April 4, 2022) – Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, provides an update on the status of its joint venture (“JV”) in China and the associated impact on first quarter 2022 revenue. As […]
Myomo To Participate in Two March Investor Conferences
BOSTON (March 9, 2022) – Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, announces that management will participate in two investor conferences during March. Read more.
Myomo Reports Fourth Quarter and Full Year 2021 Financial Results
Fourth quarter revenue of $4.0 million up 6% over prior year, full year revenue of $13.9 million up 83% over 2020 Fourth quarter gross margin of 77.4% up 400 basis points over prior year Conference call begins at 4:30 p.m. Eastern time today BOSTON (March 9, 2022) – Myomo, Inc. (NYSE American: MYO) (“Myomo” or […]
Myomo to Report Fourth Quarter and Full Year 2021 Financial Results on March 9, 2022
BOSTON, Mass., (March 2, 2022) – Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the three months and fiscal year ended December 31, 2021 on March 9, […]
Myomo Strengthens Intellectual Property Portfolio with Receipt of Key Patent in Japan
Brings the total number of patents issued on the MyoPro® device globally to 20 BOSTON (February 17, 2022) – Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, announces the granting of patent number 6998478 titled “Powered […]
Independent Research with Myomo’s MyoPro® Shows Clinically Significant Gains in Motor Function in Individuals with Chronic Moderate-to-Severe Arm Weakness
Adds to Body of Evidence Supporting the Utility of MyoPro in Stroke and Traumatic Brain Injury Patients BOSTON (February 14, 2022) – Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, announces that new research measuring the […]
Myomo To Present at the Sidoti Winter Small Cap Conference
BOSTON, Mass. (January 13, 2022) – Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that Paul Gudonis, Myomo’s chairman and chief executive officer, and David Henry, Myomo’s chief financial officer, will present at the […]
Myomo Provides Update on MyoPro® Insurance Reimbursement
BOSTON, Mass (January 10, 2022) – Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today provided an update on reimbursement for its MyoPro device by a large private payer that was denying pre-authorized claims after delivery […]
Myomo Announces MyoPro 2+
Company Continues to Innovate with Digital Technologies BOSTON, Mass. (January 6, 2022) – Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the availability of MyoPro 2+, an enhanced version of its popular MyoPro powered […]
Myomo Amends China Joint Venture Agreement, Executes Technology and Trademark License Agreement
Receipt of Full License Fee and Technology Transfer Expected to Begin before March 31, 2022 BOSTON, Mass. (January 5, 2022) – Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, announces the entry into anamended and […]